In this study, we established a model of gefitinib-induced drug-resistant lung cancer in EGFRL858R*Tp53+/− mice, which is about 35% EGFR mutation lung cancer patients, to study the effect of p53 on genomic instability and gene expression profiles. This evidence concerns the gene EGFR and lung carcinoma.